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Alzheimer’s disease (AD) is a fatal neurodegenerative disorder, and the most common
cause of dementia in the elderly. The cause of AD is not known, but genetic evidence
strongly supports the hypothesis that pathological aggregation of the β-amyloid protein (Aβ)
triggers the disease process. AD has a long preclinical phase, lasting a decade or more.
It is during this preclinical phase, before the irreversible neuron loss that characterizes the
dementia phase of the disease, that therapies are most likely to be effective. If we are to
block AD during the preclinical phase, we must identify the Aβ species that are present
before there are overt symptoms and that are associated with downstream markers of
pathology. A speciﬁc soluble Aβ assembly, the putative dodecamer “Aβ*56,” is present
in the brains and cerebrospinal ﬂuid of cognitively intact individuals and correlates with
markers of synaptic dysfunction and neuronal injury. This assembly also correlates with
memory dysfunction in multiple lines of transgenic mice that model the preclinical phase
of AD.We suggest that Aβ*56 has a critical role during the earliest phase of AD and might
serve as a molecular trigger of the disease.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of dementia
in the elderly. Age is the greatest risk factor for AD; an estimated
13% of Americans over age 65 suffer from AD, while that number
increases to 45% for those aged 85 and older (Alzheimer’s Asso-
ciation, 2012). The disease is deﬁned by characteristic lesions in
the brain – amyloid plaques composed of aggregated β-amyloid
protein (Aβ), neuroﬁbrillary tangles composed of hyperphospho-
rylated tau protein, and widespread synapse and neuron loss. In
addition to these lesions, oxidative stress, neuroinﬂammation, and
aberrant cell-cycle re-entry are among the pathological features
observed in AD brains (Mondragon-Rodriguez et al., 2010). The
cause of AD is not known, and controversy persists over which
abnormalities initiate the disease process, which are responses
that potentiate neurodegeneration, and even whether some of
these abnormalities represent protective responses of the brain
(Mondragon-Rodriguez et al., 2010).
The identiﬁcation of genes that inﬂuence susceptibility to AD
has led to insights into potential disease mechanisms. Although
most cases of AD arise sporadically, in rare cases the disease is
caused by autosomal-dominant mutations. All known mutations
that cause familial autosomal-dominant AD increase the produc-
tion of Aβ or its propensity to aggregate (reviewed in Ashe and
Zahs, 2010). Conversely, a mutation in the amyloid precursor pro-
tein (APP) that results in decreased production of Aβ protects
against sporadic AD (Jonsson et al., 2012). The best established
genetic risk factor for sporadic AD is the ε4 allele of the APOE
(apolipoprotein E) gene – compared to individuals with the most
common genotype (ε3/ε3), individuals with one copy of the ε4
allele are three times more likely to develop AD, while those with
two copies of the ε4 allele are 10–15 times more likely to develop
AD (Corder et al., 1993). While the exact role that APOE plays in
AD is not known, animal studies have shown that the rate of Aβ
clearance from the brain is differentially regulated by the various
isoforms of APOE (Castellano et al., 2011). Thus, the genetic evi-
dence points to some form of Aβ – likely a pathological aggregate –
as the molecular trigger for AD.
Mutations in tau, on the other hand, do not lead to AD, but to
a different neurodegenerative disorder, frontotemporal dementia
(FTD; Hutton et al., 1998). Transgenic mice expressing human tau
with FTD-linked mutations exhibit pronounced neurodegenera-
tion (Lewis et al., 2000; Ramsden et al., 2005; Santacruz et al., 2005;
Yoshiyama et al., 2007). Notably, many of the post-translational
modiﬁcations in tau that are promoted by FTD-linked mutations
are also seen in AD brains (Ramsden et al., 2005; Yoshiyama et al.,
2007). Furthermore, studies in animal models have shown that
Aβ potentiates tau pathology (Gotz et al., 2001; Lewis et al., 2001;
Oddo et al., 2004; Bolmont et al., 2007). Finally, tau is required
for the expression of Aβ-induced neurological abnormalities in
transgenic mice (Roberson et al., 2007).
Taken together, the evidence cited above provides strong sup-
port for the Amyloid Cascade Hypothesis, which posits that
pathogenic forms of Aβ trigger a cascade that leads to the for-
mation of toxic tau species and culminates in neuron death and
dementia. While the Amyloid Cascade Hypothesis is arguably the
primary hypothesis driving AD research today, it has its detrac-
tors (Castellani and Smith, 2011). Opponents of the hypothesis
point to the failure in clinical trials of drugs that target amyloid;
while supporters contend that treatments were administered too
late to be effective – at a timewhenneurodegeneration had become
independent of the toxic Aβ species that initiated the disease pro-
cess. To truly test the Amyloid Cascade Hypothesis will require
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intervening very early in the disease process, likely before symp-
toms are apparent, and targeting the correct form of Aβ. The
identiﬁcation of the pathogenic form(s) of Aβ is the focus of this
Perspective.
Aβ OLIGOMERS IN THE HUMAN CENTRAL NERVOUS
SYSTEM
One of the most profound questions for AD researchers today
is which Aβ species triggers the amyloid cascade. In addition to
amyloid plaques, which contain precipitates of ﬁbrillar Aβ, several
types of soluble Aβ assemblies (“oligomers”) have been described
in the brains of AD patients and transgenic mouse models of AD.
Studies conducted over the past decade indicate that oligomers,
rather than ﬁbrillar Aβ, are the predominant bioactive forms; syn-
thetic and naturally derived Aβ oligomers harm cultured neurons
and impair synaptic function and memory through a broad range
of mechanisms (reviewed in Ashe and Zahs, 2010; Kofﬁe et al.,
2011). Identifying the oligomer that initiates the amyloid cascade
is not just of academic interest – this knowledge is critical for the
development of strategies to prevent AD.
Alzheimer’s disease has a long preclinical phase, lasting a
decade or more (Sperling et al., 2011; Bateman et al., 2012; Ville-
magne et al., 2013). During this preclinical phase, people appear
cognitively intact (i.e., they score within the normal range on neu-
ropsychiatric tests), but evidence of neurological disease can be
seen through cerebrospinal ﬂuid (CSF) or brain imaging analyses.
It is during this preclinical phase, before the irreversible neuron
loss that characterizes the dementia phase of the disease, that ther-
apies are most likely to be effective. If we are to block AD during
the preclinical phase, we must identify the Aβ species that are
present before there are overt symptoms and are associated with
downstream markers of synaptic or neuronal pathology.
Two studies published this year measured levels of speciﬁc
Aβ oligomers in the brains and CSF of human subjects – both
reported that the putative dodecamer Aβ*56 (Lesné et al., 2006)
correlated with markers of neuronal dysfunction or injury in cog-
nitively normal subjects. Lesné et al. (2013) measured brain Aβ
dimers, Aβ trimers, and Aβ*56 in 140 autopsy specimens from
subjects spanning 10 decades of age. In subjects who were cog-
nitively normal at the time of death, Aβ*56, but not other Aβ
oligomers, correlated negatively with the post-synaptic markers
drebrin and Fyn kinase and positively with pathological con-
formers of tau (Lesné et al., 2013). In the ﬁrst study to measure
levels of speciﬁc Aβ oligomers in the CSF of cognitively nor-
mal older adults, Handoko et al. (2013) found that Aβ*56 was
elevated in individuals at risk for developing AD and corre-
lated strongly with levels of total tau and tau phosphorylated
at threonine-181, putative markers of neuronal injury. Inter-
estingly, the levels of Aβ*56 in the brain rose signiﬁcantly in
late middle age (Lesné et al., 2013) – considering the long dura-
tion of the preclinical phase of AD, this is the time when one
would expect the emergence of species that trigger the amyloid
cascade.
It should be noted that other Aβ assemblies, in addition to
those studied by Lesné et al. (2013) and Handoko et al. (2013),
have been described in the brains of AD patients (Noguchi et al.,
2009; Lasagna-Reeves et al., 2011). Whether these species exist in
the preclinical phase of AD and whether they are associated with
downstream markers of pathology are yet to be determined.
Aβ OLIGOMERS IN TRANSGENIC MOUSE MODELS OF
ALZHEIMER’S DISEASE
Studies in animal models have provided further insights into
the pathophysiological roles of speciﬁc oligomers. Among the
Aβ species detected in the brains of AD patients or transgenic
mouse models of AD, only two have been shown to induce neu-
ral dysfunction when isolated and injected into the brains of
healthy host animals: Aβ*56 (Lesné et al., 2006; Reed et al., 2009)
and Aβ dimers (Klyubin et al., 2008; Shankar et al., 2008; Barry
et al., 2011; our unpublished observations). Additionally, Aβ*56
correlates with memory deﬁcits in three distinct lines of APP
transgenic mice (Lesné et al., 2006, Lesné et al., 2008; Billings
et al., 2007; Cheng et al., 2007). (It might at ﬁrst seem incon-
sistent that Aβ*56 is elevated in humans who are considered
“cognitively intact,” but that it is associated with cognitive dys-
function in rodents. However, it is very possible that cognitive
decline would be revealed in these human subjects if they were
tested longitudinally using sensitive neuropsychiatric instruments
designed for detecting cognitive changes in clinically unimpaired
individuals; Rogers, 2013.) Until recently, it has been difﬁcult
to assess the effects of Aβ dimers in situ (naturally located in
the brain in which they were produced), due to a lack of ani-
mal models that generated dimers in the absence of Aβ*56. Our
laboratory recently created a novel transgenic mouse that gen-
erates abundant plaques and Aβ dimers but negligible levels of
other Aβ oligomers. These mice remain cognitively normal, even
at advanced ages. This result was surprising in view of the ex situ
studies demonstrating the toxicity of Aβ dimers, cited above. To
explain these paradoxical ﬁndings, we hypothesized that dimers
in situ are compartmentalized in a way that limits their toxi-
city. Biochemical studies have shown an intimate relationship
between dimers and plaques (Roher et al., 1996; Shankar et al.,
2008). Using laser microdissection followed by immunoblotting,
we found that dimers in situ are conﬁned to the immediate vicin-
ity of plaques, while Aβ*56 is diffusely distributed throughout
the brain parenchyma (Liu et al., 2011). We concluded that despite
their potent neurotoxicity when dispersed into cell cultures (Roher
et al., 1996; Jin et al., 2011) or into the brains of experimen-
tal hosts (Klyubin et al., 2008; Shankar et al., 2008; Barry et al.,
2011), dimers in situ exert few or no large-scale effects on brain
function.
This conclusion highlights the necessity of studying candi-
date pathogenic molecules/processes in situ in order to gain a
more genuine understanding of their effects in the brain. While
in vitro studies can provide valuable information about cellu-
lar mechanisms of action, cell culture conditions do not mimic
the spatiotemporal expression of pathogenic molecules or the
complex intercellular interactions that occur in vivo. Similarly,
exogenous administration of candidate pathogenic molecules can
show the toxic potential of these molecules, but not necessarily
their effects on neurological function when naturally produced
and localized in the brain. This caution does not apply only to
studies of Aβ– a recent essay in this series argued that extrapolating
the results of in vitro studies to the situation in vivo has resulted in
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a gross misunderstanding of the role of microglia in chronic brain
disease (Streit, 2010).
DUAL-PATHWAY MODEL FOR Aβ TOXICITY IN THE BRAIN
Based on the ﬁndings discussed above, we suggest that there are at
least two ways in which Aβ oligomers can be toxic, as illustrated in
the model in Figure 1. In this model, Aβ*56 is diffusely distributed
throughout the brain parenchyma and induces widespread synap-
tic dysfunction, which eventually leads to pathological processing
of tau and subsequent neurodegeneration over a wide area. Aβ
dimers are potently neurotoxic and induce neurodegeneration,
but the tight sequestration of dimers to the immediate vicinity of
plaques spatially restricts their inﬂuence. This model has impor-
tant implications for the development of strategies to prevent
AD. We hypothesize that, in order to prevent or delay the onset
of dementia, anti-amyloid therapies must not only be adminis-
tered early in the presymptomatic phase of the disease, but must
target Aβ*56. According to the model, strategies that target Aβ
dimers and and/or ﬁbrils might correct plaque-associated neu-
rodegenerative changes if administered early enough, but will
have little impact on the development of the widespread neuronal
dysfunction and degeneration that characterize AD.
THE ROLE OF Aβ IN AGE-RELATED COGNITIVE DECLINE
As mentioned in the Introduction, age is the greatest risk fac-
tor for AD. It is not known whether AD falls at the extreme
end of a continuum of normal age-related cognitive decline or
whether it represents a distinct pathological process. The same
mutation in APP that protects against AD also protects against
age-related cognitive decline (Jonsson et al., 2012), suggesting
that Aβ has a role in both conditions. Our laboratory previ-
ously reported that expression of transgenic APP accelerated the
appearance of age-related neural dysfunction in mice (Hsiao
et al., 1995). These studies occurred prior to the time that we
began characterizing soluble oligomers in the brains of our mice,
so we do not know which Aβ species were involved, although
notably these mice did not generate plaques. Observations in
senescence-accelerated prone mice (SAMP) are consistent with
the hypothesis that Aβ is involved in “normal” brain aging; these
mice develop deﬁcits in learning and memory at young ages
relative to the parent strain and have elevated levels of endoge-
nous mouse APP and Aβ, but no plaques (Okuma and Nomura,
1998). Administration of antibodies against Aβ or anti-sense
nucleotides that lower APP mRNA ameliorates cognitive deﬁcits
in these mice (Kumar et al., 2000; Morley et al., 2000; Banks et al.,
2001).
FUTURE DIRECTIONS AND CONCLUSIONS
The data available thus far strongly suggest that Aβ*56 is criti-
cally involved in the earliest stages of AD. However, longitudinal
studies are required to determine whether “cognitively normal”
individuals with elevated levels of Aβ*56 show accelerated rates
of cognitive decline or are indeed more likely to develop AD than
people with low levels of Aβ*56. These studies might also shed
light on the question of whether age-related cognitive decline and
AD share similar mechanisms and are indeed on a continuum
of brain aging. Such studies are still only correlative. To really
test the hypothesis that Aβ*56 is necessary to trigger the amy-
loid cascade, we must determine whether selectively decreasing
the levels of Aβ*56, or interfering with its interactions with its
FIGURE 1 | Dual-pathway model for Aβ toxicity in the brain.
The model illustrates two ways in which Aβ oligomers can be toxic:
(1) Aβ*56, which is diffusely distributed throughout the brain parenchyma,
induces widespread synaptic dysfunction, leading to pathological
processing of tau and subsequent neurodegeneration over a wide area.
(2) Aβ dimers, which are tightly sequestered around plaques, induce
neurodegeneration only in the immediate vicinity of plaques. The
area inﬂuenced by dimers is not large enough to impair cognitive
function in animals with plaque loads that approximate those found in
humans.
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cellular targets, reduces the risk of symptomatic AD. Such studies
await the development of reagents that selectively target speciﬁcAβ
oligomers.
Three well publicized AD prevention trials are scheduled to
begin this year (2013): the Alzheimer’s Prevention Initiative (API)
andDominantly InheritedAlzheimer’s Network (DIAN) trials will
test anti-amyloid therapies in asymptomatic members of families
with autosomal-dominant AD, while the Anti-amyloid Treatment
in Asymptomatic Alzheimer’s Disease (A4) trial will examine the
effects of therapy on individuals at increased risk of sporadic
AD, enrolling elderly people with who have amyloid-positive PET
scans. All of these trials will test the effects of monoclonal anti-
bodies directed against Aβ, but it is not known whether any of
the antibodies to be tested in these critical prevention trials target
Aβ*56. The API, DIAN, and A4 trials are considered by many to
be the ﬁrst true tests of the Amyloid Cascade Hypothesis. Should
these trials fail because they did not target the relevant Aβ species,
the result could be the premature rejection of the amyloid cascade
hypothesis and the abandonment of drug development programs
that target Aβ. Continued failures of clinical trials will further
undermine public conﬁdence in biomedical research and, most
importantly, delay the implementation of therapies that will lessen
the impending public health crisis that is AD. Future research clar-
ifying which forms of Aβ to target and where the targets are located
will be critical for the development of mechanism-based therapies
for AD.
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